Blockchain Registration Transaction Record

Regentis Biomaterials’ Gelrin C Targets $3B Knee Cartilage Repair Market

Regentis Biomaterials (RGNT) advances Gelrin C hydrogel for knee cartilage repair, targeting 470,000 annual procedures and $3B market. Learn about its single-stage, cell-free treatment for osteoarthritis.

Knee osteoarthritis affects millions, costing billions annually and leading to debilitating pain and reduced mobility. Regentis’ Gelrin C could offer a simpler, less invasive treatment option that may delay or prevent the need for total knee replacement, improving patient outcomes and reducing healthcare costs. For investors, the product addresses a large unmet need in a growing regenerative medicine market.